JO3037B1 - N -[5-(أمينوسلفونيل)-4- ميثيل-3،1- ثيازول-2- يل]-n- ميثيل-2-[4-(2- بيريدينيل) فنيل] أسيتاميد ميسيلات مونوهيدرات - Google Patents

N -[5-(أمينوسلفونيل)-4- ميثيل-3،1- ثيازول-2- يل]-n- ميثيل-2-[4-(2- بيريدينيل) فنيل] أسيتاميد ميسيلات مونوهيدرات

Info

Publication number
JO3037B1
JO3037B1 JOP/2012/0276A JOP20120276A JO3037B1 JO 3037 B1 JO3037 B1 JO 3037B1 JO P20120276 A JOP20120276 A JO P20120276A JO 3037 B1 JO3037 B1 JO 3037B1
Authority
JO
Jordan
Prior art keywords
methyl
aminosulfonyl
thiazol
pyridinyl
phenyl
Prior art date
Application number
JOP/2012/0276A
Other languages
English (en)
Inventor
Wilfried Schwab
Alfons Grunenberg
Alexander Birkmann
Andreas Lender
Birgit D -I Keil
Joachim Rehse
Dieter Haag
Kurt Vögtli
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Application granted granted Critical
Publication of JO3037B1 publication Critical patent/JO3037B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتخليق محسن وقصير من N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide وملح mesylate monohydrate منه باستخدام مشتقات boronic acid أو عوامل كاشفة borolane بينما يتم تجنب مركبات tin عضوية سامة وبملح mesylate monohydrate من N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide الذي يظهر زيادة الثبات طويل الأجل وإطلاق حركيات من التركيبات الدوائية.
JOP/2012/0276A 2011-09-26 2012-09-23 N -[5-(أمينوسلفونيل)-4- ميثيل-3،1- ثيازول-2- يل]-n- ميثيل-2-[4-(2- بيريدينيل) فنيل] أسيتاميد ميسيلات مونوهيدرات JO3037B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11007823A EP2573086A1 (en) 2011-09-26 2011-09-26 N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Publications (1)

Publication Number Publication Date
JO3037B1 true JO3037B1 (ar) 2016-09-05

Family

ID=46889067

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2012/0276A JO3037B1 (ar) 2011-09-26 2012-09-23 N -[5-(أمينوسلفونيل)-4- ميثيل-3،1- ثيازول-2- يل]-n- ميثيل-2-[4-(2- بيريدينيل) فنيل] أسيتاميد ميسيلات مونوهيدرات
JOP/2016/0114A JO3734B1 (ar) 2011-09-26 2016-06-07 -n[5-(أمينوسلفونيل)-4- ميثيل-3،1- ثيازول-2- يل]-n- ميثيل-2-[4-(2- بيريدينيل) فنيل] أسيتاميد ميسيلات مونوهيدرات

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2016/0114A JO3734B1 (ar) 2011-09-26 2016-06-07 -n[5-(أمينوسلفونيل)-4- ميثيل-3،1- ثيازول-2- يل]-n- ميثيل-2-[4-(2- بيريدينيل) فنيل] أسيتاميد ميسيلات مونوهيدرات

Country Status (29)

Country Link
US (1) US9340535B2 (ar)
EP (3) EP2573086A1 (ar)
JP (2) JP6161614B2 (ar)
KR (4) KR20180088530A (ar)
CN (2) CN105541829A (ar)
AR (3) AR088043A1 (ar)
AU (2) AU2012314536B2 (ar)
BR (1) BR112014003245B1 (ar)
CA (1) CA2791142C (ar)
CL (1) CL2014000149A1 (ar)
DK (2) DK2602258T3 (ar)
ES (2) ES2462492T3 (ar)
HK (1) HK1220978A1 (ar)
HR (1) HRP20140351T1 (ar)
IL (2) IL230152A (ar)
IN (1) IN2014DN01993A (ar)
JO (2) JO3037B1 (ar)
MX (2) MX338736B (ar)
MY (2) MY190878A (ar)
PE (1) PE20141148A1 (ar)
PH (1) PH12015502801B1 (ar)
PL (2) PL2602258T3 (ar)
PT (1) PT2598501E (ar)
RU (2) RU2620604C2 (ar)
SG (1) SG10201407430TA (ar)
TW (2) TWI532739B (ar)
UA (2) UA115317C2 (ar)
WO (1) WO2013045479A1 (ar)
ZA (2) ZA201401773B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
KR102354411B1 (ko) * 2016-04-06 2022-01-21 이노베이티브 몰리큘스 게엠베하 항바이러스제로서 유용한 아미노티아졸 유도체
WO2018095576A1 (en) * 2016-11-28 2018-05-31 Aicuris Anti-Infective Cures Gmbh Topical pharmaceutical formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide
AR110249A1 (es) * 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
CN117186085A (zh) 2016-11-28 2023-12-08 艾库里斯有限及两合公司 普瑞利韦硫酸盐、其药物制剂、制造方法及治疗疱疹病毒的用途
KR102335327B1 (ko) 2017-04-28 2021-12-03 현대자동차 주식회사 수냉식 이지알 쿨러
CN110831577B (zh) 2017-06-28 2023-11-28 艾库里斯有限及两合公司 包含抗病毒化合物的阴道内施用型装置
WO2019068817A1 (en) 2017-10-05 2019-04-11 Innovative Molecules Gmbh SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS
WO2020007355A1 (zh) * 2018-07-06 2020-01-09 南京明德新药研发有限公司 噻唑类化合物的晶型及其应用
CA3113353A1 (en) * 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
WO2024047508A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
WO2024047506A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024047507A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129716A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129717A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
JP2007314516A (ja) * 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd ２以上の置換基を有するベンゼン化合物を含有する医薬
JP2009539881A (ja) * 2006-06-09 2009-11-19 アイコス コーポレイション Ｄｐ−２アンタゴニストとしての置換フェニル酢酸
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Also Published As

Publication number Publication date
TWI532739B (zh) 2016-05-11
ES2466221T3 (es) 2014-06-09
KR20140066704A (ko) 2014-06-02
RU2669388C1 (ru) 2018-10-11
ES2462492T3 (es) 2014-05-23
JP2017114859A (ja) 2017-06-29
KR20180088530A (ko) 2018-08-03
DK2598501T3 (da) 2014-04-22
EP2602258A1 (en) 2013-06-12
AU2015260762B2 (en) 2016-06-09
PL2602258T3 (pl) 2014-08-29
WO2013045479A1 (en) 2013-04-04
TWI567070B (zh) 2017-01-21
TW201317234A (zh) 2013-05-01
RU2014107430A (ru) 2015-11-10
EP2602258B8 (en) 2016-09-28
CN103842359B (zh) 2016-05-25
AU2012314536B2 (en) 2016-01-14
JP6353022B2 (ja) 2018-07-04
ES2466221T8 (es) 2016-09-13
MX371088B (es) 2020-01-16
JO3734B1 (ar) 2021-01-31
EP2598501B1 (en) 2014-03-12
CN103842359A (zh) 2014-06-04
UA115317C2 (uk) 2017-10-25
DK2602258T3 (da) 2014-04-22
KR101768295B1 (ko) 2017-08-14
TW201625603A (zh) 2016-07-16
JP6161614B2 (ja) 2017-07-12
PH12015502801A1 (en) 2016-10-03
AR088043A1 (es) 2014-05-07
CA2791142A1 (en) 2013-03-26
JP2014528948A (ja) 2014-10-30
PT2598501E (pt) 2014-06-25
AR120291A2 (es) 2022-02-09
AU2012314536A1 (en) 2014-02-06
UA119574C2 (uk) 2019-07-10
NZ621615A (en) 2016-04-29
AR116394A2 (es) 2021-05-05
US20140221433A1 (en) 2014-08-07
IL234405A (en) 2015-04-30
NZ718867A (en) 2016-05-27
MX338736B (es) 2016-04-29
EP2602258B1 (en) 2014-03-19
MY190878A (en) 2022-05-13
PH12015502801B1 (en) 2016-10-03
IL230152A (en) 2015-04-30
EP2573086A1 (en) 2013-03-27
KR20190104249A (ko) 2019-09-06
AU2015260762A1 (en) 2016-02-04
MX2014003389A (es) 2014-07-09
PE20141148A1 (es) 2014-09-15
CN105541829A (zh) 2016-05-04
EP2598501A1 (en) 2013-06-05
BR112014003245B1 (pt) 2021-11-09
HK1220978A1 (zh) 2017-05-19
PL2598501T3 (pl) 2014-08-29
MY185063A (en) 2021-04-30
CA2791142C (en) 2017-08-01
BR112014003245A2 (pt) 2017-03-01
SG10201407430TA (en) 2014-12-30
ZA201408734B (en) 2016-08-31
ZA201401773B (en) 2015-12-23
HRP20140351T1 (hr) 2014-07-04
RU2620604C2 (ru) 2017-05-29
IN2014DN01993A (ar) 2015-05-15
CL2014000149A1 (es) 2014-09-05
KR20170055565A (ko) 2017-05-19
US9340535B2 (en) 2016-05-17

Similar Documents

Publication Publication Date Title
JO3734B1 (ar) -n[5-(أمينوسلفونيل)-4- ميثيل-3،1- ثيازول-2- يل]-n- ميثيل-2-[4-(2- بيريدينيل) فنيل] أسيتاميد ميسيلات مونوهيدرات
MX2014003623A (es) Monohidrato de mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol -2-il]-2-[4-(2-piridinil)-fenil]-n-metilacetamida con un intervalo de distribucion de tamaño de particula especifica y un intervalo de area superficial especifica para uso en formulaciones farmaceuticas.
MX343753B (es) Inhibidores de neprilisina.
MX342212B (es) Inhibidores de neprilisina.
PE20140831A1 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
MX348654B (es) Composicion farmaceutica con biodisponibilidad mejorada para compuesto hidrofobico de alto punto de fusion.
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
PH12016501462A1 (en) Neprilysin inhibitors
EA201590205A1 (ru) N-алкил 2-(дизамещенные)алкиниладенозин-5-уронамиды в качестве а-агонистов
PH12019500467A1 (en) Benzo-fused heterocyclic derivatives useful agonists of gpr120
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics
PE20141993A1 (es) Compuestos de benzotiazolona
CY1119984T1 (el) Σταθεροποιημενη αμορφη μορφη αγομελατινης, μια μεθοδος για την παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν
UA116877C2 (uk) Сполука з антибактеріальною і/абопротивірусною активністю
MY162537A (en) dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds
EA201590452A1 (ru) СОЛИ СОЕДИНЕНИЯ БЕНЗОТИАЗОЛОНА В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРОВ
TH147870A (th) การสังเคราะห์แบบปรับปรุงของ n-[5-(อะมิโนซัลโฟนิล)-4-เมทิล-1,3-ไทอะโซล-2-อิล]-n-เมทิล-2-[4-(2-ไพริดินิล)ฟีนิล]อะเซตะไมด์ เมซิเลต โมโนไฮเดรต
PT2602258E (pt) Monohidrato de mesilato de n-[5-aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida
UA41094U (en) Derivatives of 4-(bromomethyl)-2-r-1,3-thiazol-3-ium bromides and 4-bromomethyl-2-r-1,3-thiazoles